Oxidizing Agent for Modified Nucleotides
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,563,248 | Oxidizing Agent for Modified Nucleotides In force · High confidence | Biomodal Limited | In force | High confidence | ||
| Application 18/633,308 | Oxidising Agent for Modified Nucleotides Abandoned Abandoned Nov 26, 2024 | Biomodal Limited | Abandoned | Abandoned Nov 26, 2024 | ||
| Application 18/948,900 | Oxidising Agent for Modified Nucleotides Abandoned Abandoned Jul 21, 2025 | Biomodal Limited | Abandoned | Abandoned Jul 21, 2025 | ||
| Application 19/263,873 | Oxidising Agent for Modified Nucleotides Pending Not granted | Biomodal Limited | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Biomodal Limited.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.